# Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies

Cindy Bernelin-Cottet, Charlotte Deloizy, Ondrej Stanek, Céline Barc, Edwige Bouguyon, Celine Urien, Olivier Boulesteix, Jérémy Pezant, Charles-Adrien Richard, Mohammed Moudjou, et al.

<figure><img src="image_1.png" /></figure>

► To cite this version:

Cindy Bernelin-Cottet, Charlotte Deloizy, Ondrej Stanek, Céline Barc, Edwige Bouguyon, et al. Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies. Frontiers in Immunology, 2017, 8, pp.831. 10.3389/fimmu.2017.00831. hal-02618722

HAL Id: hal-02618722

https://hal.inrae.fr/hal-02618722

Submitted on 25 May 2020

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
<figure><img src="image_3.png" /></figure>

Check for
updates

# Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies

OPEN ACCESS

Edited and Reviewed by:
José Mordoh,
Fundación Instituto Leloir, Argentina

*Correspondence:
Isabelle Schwartz-Cornil
isabelle.schwartz@inra.fr

¹Present address:
Charlotte Deloizy
GenoSafe, Evry, France

†These authors have equally contributed to this work.

**Specialty section:**
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

**Received:** 23 June 2017
**Accepted:** 30 June 2017
**Published:** 18 July 2017

**Citation:**
Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, Boulesteix O, Pezant J, Richard C-A, Moudjou M, Costa BD, Jouneau L, Chevalier C, Leclerc C, Sebo P, Bertho N and Schwartz-Cornil I (2017) Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies. *Front. Immunol.* 8:831. doi: 10.3389/fimmu.2017.00831

Cindy Bernelin-Cottet<fnref n="1" />†, Charlotte Deloizy<fnref n="1" />†‡, Ondrej Stanek², Céline Barc³, Edwige Bouguyon<fnref n="1" />, Céline Urien<fnref n="1" />, Olivier Boulesteix³, Jérémy Pezant³, Charles-Adrien Richard<fnref n="1" />, Mohammed Moudjou<fnref n="1" />, Bruno Da Costa<fnref n="1" />, Luc Jouneau<fnref n="1" />, Christophe Chevalier<fnref n="1" />, Claude Leclerc⁴,<fnref n="5" />, Peter Sebo², Nicolas Bertho<fnref n="1" /> and Isabelle Schwartz-Cornil<fnref n="1" />*

**Keywords:** dendritic cells, swine, human, vaccines, routes of administration

## A corrigendum on

### A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies

by Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, et al. *Front Immunol* (2016) 7:641. doi:10.3389/fimmu.2016.00641

In the original article, there was an error in the CpG oligo-dinucleotide sequence used as adjuvant.

A correction has been made to the section “Materials and Methods”, paragraph “Antibodies and adjuvants”: CpG oligo-dinucleotides 5’-ggTGCATCGATTTATCGATTATCGATGCAGggggg-3’ with lower case letters for phosphorothioate linkages and upper case letters for phosphodiester linkages previously shown to be efficient in pigs (26) were bought from Sigma.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

**Conflict of Interest Statement:** CL, PS, and OS are inventors of the issued patent "A versatile delivery system for antigens or biologically active molecules." EP 09290987.8-1222, 21.12.09. No license nor royalties. The other authors declare no conflict of interest.

Copyright © 2017 Bernelin-Cottet, Deloizy, Stanek, Barc, Bouguyon, Urien, Boulesteix, Pezant, Richard, Moudjou, Costa, Jouneau, Chevalier, Leclerc, Sebo, Bertho and Schwartz-Cornil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

<footnote n="1">¹VIM-INRA-Université Paris-Saclay, Jouy-en-Josas, France, ²Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic, ³INRA, UE1277, Plate-Forme d'Infectiologie Expérimentale PFIE, Nouzilly, France, ⁴Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Equipe Labellisée Ligue Contre le Cancer, Paris, France,</footnote>

<footnote n="5">⁵INSERM U1041, Unité de Régulation Immunitaire et Vaccinologie, Département Immunologie, Paris, France</footnote>